Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease; BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a. It also intends to develop BEAM-103, an anti-CD117 monoclonal antibody, and BEAM-104, a cell therapy for development in sickle cell disease and beta-thalassemia; and BEAM-201 and other potential ex vivo CAR-T therapies. The company has research collaboration agreement with Pfizer Inc., focus on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Apellis Pharmaceuticals to conduct preclinical research on target specific genes within the complement system in various organs, including the eye, liver, and brain; Verve Therapeutics, Inc., for cardiovascular disease treatments; Sana Biotechnology, Inc., to research, develop, and commercialize rights to CRISPR Cas12b for cell therapy programs; and Orbital Therapeutics design RNA for the prevention, treatment or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.

Beam Therapeutics Inc.

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Beam Therapeutics (BEAM), OmniAb (OABI) and Astrana ...

Analysts Offer Insights on Healthcare Companies: Beam Therapeutics (BEAM), OmniAb (OABI) and Astrana Health (ASTH)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Gilead Sciences (GILD), Ultragenyx Pharmaceutical (RARE) and Beam...

Analysts Offer Insights on Healthcare Companies: Gilead Sciences (GILD), Ultragenyx Pharmaceutical (RARE) and Beam Therapeutics (BEAM)

RBC Capital analyst Luca Issi reiterated a Hold rating on Beam Therapeutics today and set a price target of $26.00. Issi covers the Healthcare sect...

RBC Capital Keeps Their Hold Rating on Beam Therapeutics (BEAM)

In a report released today, William Maughan from Clear Street maintained a Buy rating on Beam Therapeutics, with a price target of $37.00. Accordin...

Clear Street Remains a Buy on Beam Therapeutics (BEAM)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Harmony Biosciences Holdings (HRMY) and Beam Therape...

Analysts Are Bullish on These Healthcare Stocks: Harmony Biosciences Holdings (HRMY), Beam Therapeutics (BEAM)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Beam Therapeutics (BEAM), Rhythm Pharmaceuticals (RY...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	BEAM	$26.57	-1.96%	1.19M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	BEAM	$26.57	-2.0%	1.19M
3
4
5
6

BEAM

Get Beam Therapeutics Inc. Data in Excel

Get Beam Therapeutics Inc. Data in Excel